Recombinant Human IL-18/IL-1F4 Protein Best Seller
R&D Systems, part of Bio-Techne | Catalog # 9124-IL
Key Product Details
Product Specifications
Source
Tyr37-Asp193
Purity
Endotoxin Level
N-terminal Sequence Analysis
Predicted Molecular Mass
SDS-PAGE
Activity
The ED50 for this effect is 1.5-9 ng/mL.
Reviewed Applications
Read 11 reviews rated 4.6 using 9124-IL in the following applications:
Scientific Data Images for Recombinant Human IL-18/IL-1F4 Protein
Recombinant Human IL‑18/IL‑1F4 Protein SEC-MALS.
Recombinant Human IL-18 (Catalog # 9124-IL) has a molecular weight (MW) of 17.5 kDa as analyzed by SEC-MALS, suggesting that this protein is a monomer.Recombinant Human IL-18/IL-1F4 Protein Bioactivity
Recombinant Human IL-18 (Catalog # 9124-IL) induces IFN-gamma secretion by KG‑1 human acute myelogenous leukemia cells. The ED50 for this effect is 1.5-9 ng/mL.Recombinant Human IL-18/IL-1F4 Protein SDS-PAGE
1 μg/lane of Recombinant Human IL-18/IL-1F4 (Catalog # 9124-IL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing a single band at 18 kDa.Formulation, Preparation and Storage
Carrier Free
What does CF mean?CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
What formulation is right for me?In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
Carrier: 9124-IL
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS and DTT with BSA as a carrier protein. |
Reconstitution | Reconstitute at 200 μg/mL in PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Carrier Free: 9124-IL/CF
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS and DTT. |
Reconstitution | Reconstitute at 200 μg/mL in PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: IL-18/IL-1F4
IL-18 activation is induced by infection or tissue damage and contributes to disease pathology in chronic inflammation (1-3). IL-18 binds to the widely expressed
IL-18 R alpha which recruits IL-18 R beta to form the signaling receptor complex (4, 5). Its bioactivity is negatively regulated by interactions with IL-18 binding proteins and virally encoded IL-18BP homologs (6). In the presence of IL-12 or IL-15, IL-18 enhances anti-viral Th1 immune responses by inducing IFN-gamma production and the cytolytic activity of CD8+ T cells and NK cells (7, 8). In the absence of IL-12 or IL-15, however, IL-18 promotes production of the Th2 cytokines IL-4 and IL-13 by CD4+ T cells and basophils (9, 10). In the presence of IL-1 beta or IL-23, IL-18 induces the antigen-independent production of IL-17 by gamma delta T cells and CD4+ T cells (11).
IL-18 also promotes myeloid dendritic cell maturation and triggers neutrophil respiratory burst (12, 13). In cancer, IL-18 exhibits diverse activities including enhancing anti-tumor immunity, inhibiting or promoting angiogenesis, and promoting tumor cell metastasis (14). Mature human IL-18 shares approximately 63% amino acid sequence identity with mouse and rat IL-18 (15). Alternative splicing in human ovarian cancer generates an isoform that is resistant to Caspase-1 activation (16). A cell surface form can be expressed on M-CSF induced macrophages and released in response to bacterial endotoxin (17).
References
- Dinarello, C.A. et al. (2013) Front. Immunol. 4:289.
- Smith, D.E. (2011) J. Leukoc. Biol. 89:383.
- Gu, Y. et al. (1997) Science 275:206.
- Torigoe, K. et al. (1997) J. Biol. Chem. 272:25737.
- Cheung, H. et al. (2005) J. Immunol. 174:5351.
- Novick, D. et al. (1999) Immunity 10:127.
- Fehniger, T.A. et al. (1999) J. Immunol. 162:4511.
- Yoshimoto, T. et al. (1998) J. Immunol. 161:3400.
- Yoshimoto, T. et al. (2000) Nat. Immunol. 1:132.
- Kroeger, K.M. et al. (2009) J. Leukoc. Biol. 86:769.
- Lalor, S.J. et al. (2011) J. Immunol. 186:5738.
- Li, J. et al. (2004) Cell. Immunol. 227:103.
- Elbim, C. et al. (2005) Clin. Diagn. Lab. Immunol. 12:436.
- Fabbi, M. et al. (2015) J. Leukoc. Biol. 97:665.
- Ushio, S. et al. (1996) J. Immunol. 156:4274.
- Gaggero, A. et al. (2004) Oncogene 23:7552.
- Bellora, F. et al. (2012) Eur. J. Immunol. 42:1618.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional IL-18/IL-1F4 Products
Product Documents for Recombinant Human IL-18/IL-1F4 Protein
Product Specific Notices for Recombinant Human IL-18/IL-1F4 Protein
For research use only